肌萎缩侧索硬化

Brooks BR, Miller RG, Swash M, et al; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293-299.

• 摘要

Miller RG, Jackson CE, Kasarskis EJ, et al; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review). Neurology. 2009;73:1227-1233.

• 全文
• 摘要

Miller RG, Jackson CE, Kasarskis EJ, et al; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review). Neurology. 2009;73:1218-1226. [Errata in: Neurology. 2009;73:2134; Neurology. 2010;74:781.]

• 全文
• 摘要

1.  Gordon PH, Cheng B, Katz IB, et al. The natural history of primary lateral sclerosis. Neurology. 2006;66:647-653.

• 摘要

2.  Tartaglia MC, Rowe A, Findlater K, et al. Differentiation between primary lateral sclerosis and amyotrophic lateral sclerosis: examination of symptoms and signs at disease onset and during follow-up. Arch Neurol. 2007;64:232-236.

• 全文
• 摘要

3.  Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546-1554.

• 摘要

4.  Neary D, Snowden J, Mann D. Frontotemporal dementia. Lancet Neurol. 2005;4:771-780.

• 摘要

5.  Beck M, Giess R, Magnus T, et al. Progressive sudomotor dysfunction in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2002;73:68-70.

• 摘要

6.  Shimizu T, Kawata A, Kato S, et al. Autonomic failure in ALS with a novel SOD1 gene mutation. Neurology. 2000;54:1534-1537.

• 摘要

7.  Worms PM. The epidemiology of motor neuron diseases: a review of recent studies. J Neurol Sci. 2001;191:3-9.

• 摘要

8.  Cronin S, Hardiman O, Traynor BJ. Ethnic variation in the incidence of ALS: a systematic review. Neurology. 2007;68:1002-1007.

• 摘要

9.  Lin CL, Bristol LA, Jin L, et al. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron. 1998;20:589-602.

• 摘要

10.  Kawahara Y, Ito K, Sun H, et al. Glutamate receptors: RNA editing and death of motor neurons. Nature. 2004;427:801.

• 摘要

11.  Rockenstein E, Crews L, Masliah E. Transgenic animal models of neurodegenerative diseases and their application to treatment development. Adv Drug Deliv Rev. 2007;59:1093-1102.

• 摘要

12.  Okado-Matsumoto A, Fridovich, I. Amyotrophic lateral sclerosis: a proposed mechanism. Proc Natl Acad Sci U S A. 2002;99:9010-9014.

• 全文
• 摘要

13.  Urushitani M, Kurisu J, Tsukita K, et al. Proteasomal inhibition by misfolded mutant superoxide dismutase 1 induces selective motor neuron death in familial amyotrophic lateral sclerosis. J Neurochem. 2002;83:1030-1042.

• 摘要

14.  Rakhit R, Cunningham P, Furtos-Matei A, et al. Oxidation-induced misfolding and aggregation of superoxide dismutase and its implications for amyotrophic lateral sclerosis. J Biol Chem. 2002;277:47551-47556.

• 全文
• 摘要

15.  Lipton SA, Gu Z, Nakamura T. Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders. Int Rev Neurobiol. 2007;82:1-27.

• 摘要

16.  Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59-62.

• 摘要

17.  Borchelt DR. Amyotrophic lateral sclerosis - are microglia killing motor neurons? N Engl J Med. 2006;355:1611-1613.

• 摘要

18.  Beal MF. Mitochondria take center stage in aging and neurodegeneration. Ann Neurol. 2005;58:495-505.

• 摘要

19.  Lin H, Schlaepfer WW. Role of neurofilament aggregation in motor neuron disease. Ann Neurol. 2006;60:399-406.

• 摘要

20.  van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390(10107):2084-2098.

• 全文
• 摘要

21.  Benatar M, Kurent J, Moore DH. Treatment for familial amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2009;(1):CD006153.

• 摘要

22.  Lee CN. Reviewing evidences on the management of patients with motor neuron disease. Hong Kong Med J. 2012;18:48-55.

• 全文
• 摘要

23.  Andersen PM, Sims KB, Xin WW, et al. Sixteen novel mutations in the Cu/Zn superoxide dismutase gene in amyotrophic lateral sclerosis: a decade of discoveries, defects and disputes. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4:62-73.

• 摘要

24.  Rowland LP. Hereditary and acquired motor neuron diseases. In: Rowland LP, ed. Merritt's Neurology. 10th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2000:708-714.

25.  Pablo J, Banack SA, Cox PA, et al. Cyanobacterial neurotoxin BMAA in ALS and Alzeimer’s disease. Acata Neurol Scand. 2009;120:216-225.

• 摘要

26.  Kuzuhara S. Revisit to Kii ALS - the innovated concept of ALS-Parkinsonism-dementia complex, clinicopathological features, epidemiology and etiology. Brain Nerve. 2007;59:1065-1074.

• 摘要

27.  Weisskopf MG, O'Reilly EJ, McCullough ML, et al. Prospective study of military service and mortality from ALS. Neurology. 2005;64:32-37.

• 摘要

28.  Veldink JH, Kalmijn S, Groeneveld GJ, et al. Physical activity and the association with sporadic ALS. Neurology. 2005;64:241-245.

• 摘要

29.  Chio A, Benzi G, Dossena M, et al. Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. Brain. 2005;128:472-476.

• 全文
• 摘要

30.  Kamel F, Umbach DM, Munsat TL, et al. Association of cigarette smoking with amyotrophic lateral sclerosis. Neuroepidemiology. 1999;18:194-202.

• 摘要

31.  Nelson LM, McGuire V, Longstreth WT Jr, et al. Population-based case control study of amyotrophic lateral sclerosis in western Washington State. I. Cigarette smoking and alcohol consumption. Am J Epidemiol. 2000;151:156-163.

• 全文
• 摘要

32.  Alonso A, Logroscino G, Hernán MA. Smoking and the risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2010;81:1249-1252.

• 摘要

33.  Armon C. Smoking may be considered an established risk factor for sporadic ALS. Neurology. 2009;73:1693-1698.

• 全文
• 摘要

34.  McGuire V, Longstreth WT Jr, Nelson LM, et al. Occupational exposures and amyotrophic lateral sclerosis. A population-based case-control study. Am J Epidemiol. 1997;145:1076-1088.

• 全文
• 摘要

35.  Kamel F, Umbach DM, Munsat TL, et al. Lead exposure and amyotrophic lateral sclerosis. Epidemiology. 2002;13:311-319.

• 摘要

36.  Mitsumoto H, Chad DA, Pioro EP. Amyotrophic lateral sclerosis. In: Contemporary neurology series, volume 49. Philadelphia, PA: FA Davis; 1998:480.

37.  Rowland LP, Muscular Dystrophy Association. Amyotrophic lateral sclerosis and other motor neuron diseases. In: Advances in neurology, volume 56. New York, NY: Raven Press; 1991:569.

38.  Brooks BR, Sanjak M, Belden D, et al. Natural history in amyotrophic lateral sclerosis - impairment, disability, handicap. In: Brown RH Jr., Meininger V, Swash M, eds. Amyotrophic lateral sclerosis. London: Dunitz; 2000:31-58.

39.  Shoesmith CL, Findlater K, Rowe A, et al. Prognosis of amyotrophic lateral sclerosis with respiratory onset. J Neurol Neurosurg Psychiatry. 2007;78:629-631.

• 摘要

40.  Filippi M, Agosta F, Abrahams S; European Federation of Neurological Societies. EFNS guidelines on the use of neuroimaging in the management of motor neuron diseases. Eur J Neurol. 2010;17:526-e20.

• 全文
• 摘要

41.  Shipe C, Zivkovic SA. Electrodiagnostic evaluation of motor neuron disorders. Am J Electroneurodiagnostic Technol. 2004;44:30-36.

• 摘要

42.  de Carvalho M, Swash M. Nerve conduction studies in amyotrophic lateral sclerosis. Muscle Nerve. 2000;23:344-352.

• 摘要

43.  Daube JR. Electrodiagnostic studies in amyotrophic lateral sclerosis and other motor neuron disorders. Muscle Nerve. 2000;23:1488-1502.

• 摘要

44.  Raaphorst J, de Visser M, Linssen WH, et al. The cognitive profile of amyotrophic lateral sclerosis: a meta-analysis. Amyotroph Lateral Scler. 2010;11:27-37.

• 摘要

45.  Lomen-Hoerth C. Characterization of amyotrophic lateral sclerosis and frontotemporal dementia. Dement Geriatr Cogn Disord. 2004;17:337-341.

• 摘要

46.  Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology. 2002;59:1077-1079.

• 摘要

47.  Kornberg, AJ, Pestronk A. The clinical and diagnostic role of anti-GM1 antibody testing. Muscle Nerve. 1994;17:100-104.

• 摘要

48.  Pestronk A, Cornblath DR, Ilyas AA, et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol. 1988;24:73-78.

• 摘要

49.  Gourie-Devi M, Nalini A. Long-term follow-up of 44 patients with brachial monomelic amyotrophy. Acta Neurol Scand. 2003;107:215-220.

• 摘要

50.  Blexrud MD, Windebank AJ, Daube JR. Long-term follow-up of 121 patients with benign fasciculations. Ann Neurol. 1993;34:622-625.

• 摘要

51.  Chasens ER, Umlauf MG. Post-polio syndrome. Am J Nurs. 2000;100:60-63;65;67.

• 摘要

52.  Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci. 1994 Jul;124 Suppl:96-107.

• 摘要

53.  Brooks BR, Miller RG, Swash M, et al; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293-299.

• 摘要

54.  Miller RG, Jackson CE, Kasarskis EJ, et al; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review). Neurology. 2009;73:1227-1233.

• 全文
• 摘要

55.  Van den Berg JP, Kalmijn S, Lindeman E, et al. Multidisciplinary ALS care improves quality of life in patients with ALS. Neurology. 2005;65:1264-1267.

• 摘要

56.  Chio A, Bottacchi E, Buffa C, et al. Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities. J Neurol Neurosurg Psychiatry. 2006;77:948-950.

• 摘要

57.  Borasio GD, Voltz R, Miller RG. Palliative care in amyotrophic lateral sclerosis. Neurol Clin. 2001;19:829-847.

• 摘要

58.  Munroe CA, Sirdofsky MD, Kuru T, et al. End-of-life decision making in 42 patients with amyotrophic lateral sclerosis. Respir Care. 2007;52:996-999.

• 全文
• 摘要

59.  Andersen PM, Abrahams S, Borasio GD, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS) - revised report of an EFNS task force. Eur J Neurol. 2012;19:360-375.

• 摘要

60.  Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;(3):CD001447.

• 全文
• 摘要

61.  Miller RG, Jackson CE, Kasarskis EJ, et al; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review). Neurology. 2009;73:1218-1226. [Errata in: Neurology. 2009;73:2134; Neurology. 2010;74:781.]

• 全文
• 摘要

62.  Jia H, Xu YM. Evidence-based evaluation of therapeutic measures for amyotrophic lateral sclerosis [in Chinese]. Chin J Contemp Neurol Neurosurg. 2012;12:275-281.

• 全文

63.  Bensimon G, Lacomblez L, Meininger V; ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994;330:585-591.

• 全文
• 摘要

64.  Weber G, Bitterman H. Riluzole-induced neutropenia. Neurology. 2004;62:1648.

• 摘要

65.  Sanofi-Aventis. Rilutek® (riluzole) tablets: prescribing information. November 2012. http://products.sanofi.us

• 全文

66.  National Institute for Health and Care Excellence. Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure caused by motor neurone disease. September 2017 [internet publication].

• 全文

67.  Morgan RK, McNally S, Alexander M, et al. Use of Sniff nasal-inspiratory force to predict survival in amyotrophic lateral sclerosis. Am J Respir Crit Care Med. 2005;171:269-274.

• 全文
• 摘要

68.  National Institute for Health and Care Excellence. Motor neurone disease. July 2016 [internet publication]

• 全文

69.  Radunovic A, Annane D, Rafiq MK, et al. Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2017 Oct 6;10:CD004427.

• 全文
• 摘要

70.  Aboussouan LS, Khan SU, Meeker DP, et al. Effect of noninvasive positive-pressure ventilation on survival in amyotrophic lateral sclerosis. Ann Intern Med. 1997;127:450-453.

• 摘要

71.  Lo Coco D, Marchese S, Pesco MC, et al. Noninvasive positive-pressure ventilation in ALS: predictors of tolerance and survival. Neurology. 2006;67:761-765.

• 摘要

72.  Rabinstein AA, Wijdicks EF. Warning signs of imminent respiratory failure in neurological patients. Semin Neurol. 2003;23:97-104.

• 摘要

73.  McKim DA, Road J, Avendano M, et al; Canadian Thoracic Society Home Mechanical Ventilation Committee. Home mechanical ventilation: a Canadian Thoracic Society clinical practice guideline. Can Respir J. 2011;18:197-215.

• 全文
• 摘要

74.  Moss AH, Casey P, Stocking CB, et al. Home ventilation for amyotrophic lateral sclerosis patients: outcomes, costs, and patient, family, and physician attitudes. Neurology. 1993;43:438-443.

• 摘要

75.  Simon ST, Higginson IJ, Booth S, et al. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev. 2016;(10):CD007354.

• 全文
• 摘要

76.  Katzberg, HD, Benatar M. Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2011;(1):CD004030.

• 全文
• 摘要

77.  Chio A, Finnochiaro E, Meineri P, et al; ALS Percutaneous Endoscopic Gastrostomy Study Group. Safety and factors related to survival after percutaneous endoscopic gastrostomy in ALS. Neurology. 1999;53:1123-1125.

• 摘要

78.  ProGas Study Group. Gastrostomy in patients with amyotrophic lateral sclerosis (ProGas): a prospective cohort study. Lancet Neurol. 2015;14:702-709.

• 全文
• 摘要

79.  Stone CA, O'Leary N. Systematic review of the effectiveness of botulinum toxin or radiotherapy for sialorrhea in patients with amyotrophic lateral sclerosis. J Pain Symptom Manage. 2009;37:246-258.

• 摘要

80.  Tysnes OB. Treatment of sialorrhea in amyotrophic lateral sclerosis. Acta Neurol Scand Suppl. 2008;188:77-81.

• 摘要

81.  McGeachan AJ, Mcdermott CJ. Management of oral secretions in neurological disease. Pract Neurol. 2017;17:96-103.

• 全文
• 摘要

82.  Pioro EP, Brooks BR, Cummings J, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol. 2010;68:693-702.

• 摘要

83.  Lui AJ, Byl NN. A systematic review of the effect of moderate intensity exercise on function and disease progression in amyotrophic lateral sclerosis. J Neurol Physical Therapy. 2009;33:68-87.

• 摘要

84.  Dal Bello-Haas V, Florence JM. Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst Rev. 2013;(5):CD005229.

• 全文
• 摘要

85.  Newrick PG, Langton-Hewer R. Pain in motor neuron disease. J Neurol Neurosurg Psychiatry. 1985;48:838-840.

• 摘要

86.  Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage. 2004;28:140-175.

• 摘要

87.  Rabkin JG, Albert SM, Del Bene ML, et al. Prevalence of depressive disorders and change over time in late-stage ALS. Neurology. 2005;65:62-67.

• 全文
• 摘要

88.  Practice advisory on the treatment of amyotrophic lateral sclerosis with riluzole: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 1997;49:657-659.

• 摘要

89.  Dorst J, Cypionka J, Ludolph AC. High-caloric food supplements in the treatment of amyotrophic lateral sclerosis: a prospective interventional study. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:533-536.

• 摘要

90.  Costa J, Rocha ML, Ferreira J, et al. Botulinum toxin type-B improves sialorrhea and quality of life in bulbar onset amyotrophic lateral sclerosis. J Neurol. 2008;255:545-550.

• 摘要

91.  Lipp A, Trottenberg T, Schink T, et al. A randomized trial of botulinum toxin A for treatment of drooling. Neurology. 2003;61:1279-1281.

• 摘要

92.  Writing Group; Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505-512.

• 摘要

93.  Weiss MD, Macklin EA, Simmons Z, et al; Mexiletine ALS Study Group. A randomized trial of mexiletine in ALS: safety and effects on muscle cramps and progression. Neurology. 2016;86:1474-1481.

• 全文
• 摘要

94.  Beghi E, Pupillo E, Bonito V, et al; Italian ALS Study Group. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:397-405.

• 摘要

95.  DiPALS Writing Committee; DiPALS Study Group Collaborators, McDermott CJ, Bradburn MJ, et al. Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial. Lancet Neurol. 2015;14:883-892.

• 全文
• 摘要

96.  Gonzalez-Bermejo J, Morélot-Panzini C, Tanguy ML, et al. Early diaphragm pacing in patients with amyotrophic lateral sclerosis (RespiStimALS): a randomised controlled triple-blind trial. Lancet Neurol. 2016;15:1217-1227.

• 摘要

97.  Abdul Wahid SF, Law ZK, Ismail NA, et al. Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2016 Nov 8;11:CD011742.

• 全文
• 摘要

98.  ClinicalTrials.gov. The objective is to compare the efficacy and safety of masitinib in combination with riluzole in the treatment of patients suffering from amyotrophic lateral sclerosis (ALS): NCT02588677. http://clinicaltrials.gov

• 全文

99.  ClinicalTrials.gov. Ibudilast (MN-166) in subjects with amyotrophic lateral sclerosis (ALS) (IBU-ALS-1201): NCT02238626. http://clinicaltrials.gov

• 全文

100.  ClinicalTrials.gov. AMX0035 in Patients with Amyotrophic Lateral Sclerosis (CENTAUR): NCT03127514 [internet publication].

• 全文

101.  ClinicalTrials.gov. Efficacy and Tolerability of Tauroursodeoxycholic Acid in Amyotrophic Lateral Sclerosis (TUDCA-ALS): NCT00877604. November 2014 [internet publication]. 

• 全文

102.  ClinicalTrials.gov. Single and multiple dose study of BIIB067 in adults with amyotrophic lateral sclerosis (ALS): NCT02623699. http://clinicaltrials.gov

• 全文

103.  Turner MR, Parton MJ, Shaw CE, et al. Prolonged survival in motor neuron disease: a descriptive study of the King's database 1990-2002. J Neurol Neurosurg Psychiatry. 2003;74:995-997.

• 摘要

104.  Chiò A, Logroscino G, Hardiman O, et al; Eurals Consortium. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10:310-323.

• 摘要

105.  Jablecki CK, Berry C, Leach J. Survival prediction in amyotrophic lateral sclerosis. Muscle Nerve. 1989;12:833-841.

• 摘要

106.  Eisen A, Schulzer M, MacNeil M, et al. Duration of amyotrophic lateral sclerosis is age dependent. Muscle Nerve. 1993;16:27-32.

• 摘要

107.  Czaplinski A, Yen AA, Appel SH. Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry. 2006;77:390-392.

• 摘要